利伐沙班与低分子肝素及磺达肝癸钠预防高原居民全膝关节置换术后深静脉血栓的随机对照试验
本研究为随机对照试验,纳入90例长期居住在海拔≥1500米的高原居民,比较利伐沙班、低分子肝素和磺达肝癸钠预防全膝关节置换术后深静脉血栓的疗效与安全性。主要结局为术后第14天超声诊断的DVT发生率,利伐沙班组为0%,低分子肝素组16.7%,磺达肝癸钠组13.3%(P=0.016)。利伐沙班降低D-二聚体和炎症指标且不增加出血风险。
要点
- 高原居民TKA术后利伐沙班DVT发生率0%,低于低分子肝素16.7%和磺达肝癸钠13.3%。
- 利伐沙班术后第14天D-二聚体显著低于两对照组,PT和APTT高于两对照组。
- 利伐沙班CRP和PCT显著更低,出血并发症与两对照组相当。
核心结论
- 高原居民TKA术后使用利伐沙班预防DVT疗效优于低分子肝素和磺达肝癸钠,且不增加出血风险。
研究设计与样本
- 随机对照试验,纳入90例长期居住海拔≥1500米的高原居民,行初次全膝关节置换术。
- 随机分为三组:利伐沙班组(A组)、低分子肝素组(B组)、磺达肝癸钠组(C组)。
- 主要结局为术后第14天双功超声评估的DVT发生率。
主要发现
- DVT发生率:利伐沙班组0%,低分子肝素组16.7%,磺达肝癸钠组13.3%(P=0.016)。
- 术后第14天D-二聚体:利伐沙班组低于低分子肝素组(P<0.001)和磺达肝癸钠组(P<0.001),磺达肝癸钠组低于低分子肝素组(P<0.001)。
- PT和APTT:利伐沙班组高于低分子肝素组(PT P<0.001,APTT P=0.012)和磺达肝癸钠组(PT P<0.001,APTT P=0.035)。
- CRP和PCT:利伐沙班组低于低分子肝素组(CRP P<0.001,PCT P<0.001)和磺达肝癸钠组(CRP P=0.018,PCT P=0.018)。
- FIB、PLT、IL-6、ESR、WBC、术中出血量及出血并发症组间无显著差异。
关键数值与推荐
- 高原居住定义为海拔≥1500米。
- DVT通过术后第14天双功超声评估。
- DVT发生率组间比较P=0.016。
临床怎么用
- 对于长期居住高原的行全膝关节置换术患者,利伐沙班可作为预防术后DVT的优先抗凝选择。
- 利伐沙班在降低DVT发生率的同时不增加出血风险,且有助于减轻炎症反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-altitude residence (defined as ≥ 1500 m above sea level) is associated with chronic hypoxia and increased thrombotic risk. This study aimed to evaluate the comparative efficacy and safety of rivaroxaban, low-molecular-weight heparin (LMWH), and fondaparinux for preventing deep vein thrombosis (DVT) after total knee arthroplasty (TKA) in long-term high-altitude residents. METHODS: In this randomized controlled trial, 90 high-altitude residents undergoing primary TKA were randomly assigned to one of three groups: rivaroxaban (group A), LMWH (group B), or fondaparinux (group C). The primary outcome was the incidence of postoperative DVT assessed by duplex ultrasonography on postoperative day 14. Secondary outcomes included coagulation indicators (PT, APTT, FIB, PLT, D-dimer), inflammatory markers (CRP, PCT, IL-6, ESR, WBC), knee circumference, intraoperative blood loss, and bleeding-related adverse events. RESULTS: DVT incidence was 0% in the rivaroxaban group, compared with 16.7% in the LMWH group and 13.3% in the fondaparinux group (P = 0.016). On postoperative day 14, D-dimer levels were significantly lower in the rivaroxaban group than in LMWH (P < 0.001) and fondaparinux (P < 0.001) and lower in fondaparinux than LMWH (P < 0.001). PT and APTT were higher in the rivaroxaban group compared with LMWH (PT P < 0.001, APTT P = 0.012) and fondaparinux (PT P < 0.001, APTT P = 0.035). FIB and PLT showed no significant differences. CRP and PCT were significantly lower with rivaroxaban than LMWH (CRP P < 0.001, PCT P < 0.001) and fondaparinux (CRP P = 0.018, PCT P = 0.018), while IL-6, ESR, and WBC showed no group differences. Intraoperative blood loss and bleeding complications were comparable across groups. CONCLUSION: Among high-altitude residents undergoing TKA, rivaroxaban demonstrated superior efficacy in preventing postoperative DVT and reducing inflammatory response without increasing bleeding risk. These findings contribute important evidence to guide anticoagulant selection in populations living at high altitude, who face unique thrombotic challenges due to chronic hypoxia.
引用
- Ren L, Fang H, Fu X, et al. Rivaroxaban versus low-molecular-weight heparin and fondaparinux for preventing deep vein thrombosis after total knee arthroplasty in high-altitude residents: a randomized controlled trial. Trials. 2026. PMID: 42260637. doi:10.1186/s13063-025-09371-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。